pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
Company profile
Ticker
PLSE
Exchange
Website
CEO
Darrin R. Uecker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Electroblate, Inc.
SEC CIK
Corporate docs
Subsidiaries
NanoBlate Corp. • BioElectroMed Corp. • Pulse Biosciences BV • 2783162 Ontario Inc. ...
PLSE stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
19 Aug 24
NT 10-Q
Notice of late quarterly filing
15 Aug 24
8-K
Regulation FD Disclosure
12 Aug 24
8-K
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
12 Aug 24
8-K
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
8 Aug 24
8-K
Entry into a Material Definitive Agreement
15 Jul 24
424B5
Prospectus supplement for primary offering
15 Jul 24
S-3MEF
Registration of additional securities for an S-3
15 Jul 24
8-K
Other Events
8 Jul 24
8-K
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
3 Jul 24
Transcripts
PLSE
Earnings call transcript
2024 Q2
12 Aug 24
PLSE
Earnings call transcript
2024 Q1
7 May 24
PLSE
Earnings call transcript
2023 Q4
28 Mar 24
PLSE
Earnings call transcript
2023 Q3
13 Nov 23
PLSE
Earnings call transcript
2023 Q2
10 Aug 23
PLSE
Earnings call transcript
2023 Q2
10 Aug 23
PLSE
Earnings call transcript
2023 Q1
11 May 23
PLSE
Earnings call transcript
2022 Q4
30 Mar 23
PLSE
Earnings call transcript
2022 Q3
11 Nov 22
PLSE
Earnings call transcript
2022 Q2
10 Aug 22
Latest ownership filings
4
Mitchell E. Levinson
30 Sep 24
4
PAUL A LAVIOLETTE
13 Aug 24
3
PAUL A LAVIOLETTE
13 Aug 24
4
Manmeet Singh Soni
13 Aug 24
4
Mahkam Zanganeh
13 Aug 24
4
Burke Thomas Barrett
22 Jul 24
4
Mahkam Zanganeh
9 Jul 24
4
ROBERT W DUGGAN
9 Jul 24
4
Kevin Patrick Danahy
9 Jul 24
4
Mitchell E. Levinson
8 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.20 mm | 26.20 mm | 26.20 mm | 26.20 mm | 26.20 mm | 26.20 mm |
Cash burn (monthly) | 2.90 mm | 2.71 mm | 3.91 mm | 3.84 mm | 2.80 mm | 2.95 mm |
Cash used (since last report) | 10.88 mm | 10.19 mm | 14.68 mm | 14.43 mm | 10.51 mm | 11.09 mm |
Cash remaining | 15.32 mm | 16.01 mm | 11.52 mm | 11.76 mm | 15.69 mm | 15.10 mm |
Runway (months of cash) | 5.3 | 5.9 | 2.9 | 3.1 | 5.6 | 5.1 |
Institutional ownership, Q2 2024
8.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 46 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 53.77 bn |
Total shares | 5.32 mm |
Total puts | 96.20 k |
Total calls | 138.30 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 1.15 mm | $12.83 bn |
Vanguard | 905.39 k | $10.13 bn |
BAC Bank of America | 782.58 k | $8.76 bn |
Duggan Robert W | 492.07 k | $4.62 mm |
Geode Capital Management | 423.97 k | $4.75 bn |
STT State Street | 391.64 k | $4.38 bn |
Griffin Asset Management | 257.68 k | $2.88 bn |
NTRS Northern Trust | 181.17 k | $2.03 bn |
Westside Investment Management | 63.60 k | $711.68 mm |
Nuveen Asset Management | 60.34 k | $675.16 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Sep 24 | Levinson Mitchell E. | Common Stock | Acquire X | Yes | No | 11 | 322 | 3.54 k | 8,521 | |
24 Sep 24 | Levinson Mitchell E. | Common Stock | Acquire X | Yes | No | 11 | 322 | 3.54 k | 8,421 | |
24 Sep 24 | Levinson Mitchell E. | Common Stock | Acquire X | Yes | No | 11 | 322 | 3.54 k | 8,321 | |
24 Sep 24 | Levinson Mitchell E. | Common Stock | Acquire X | Yes | No | 11 | 1,240 | 13.64 k | 21,240 | |
24 Sep 24 | Levinson Mitchell E. | Common Stock | Acquire X | No | No | 11 | 3,000 | 33.00 k | 93,880 | |
24 Sep 24 | Levinson Mitchell E. | Warrant Common Stock | Dispose X | Yes | No | 11 | 161 | 1.77 k | 0 | |
24 Sep 24 | Levinson Mitchell E. | Warrant Common Stock | Dispose X | Yes | No | 11 | 161 | 1.77 k | 0 | |
24 Sep 24 | Levinson Mitchell E. | Warrant Common Stock | Dispose X | Yes | No | 11 | 161 | 1.77 k | 0 | |
24 Sep 24 | Levinson Mitchell E. | Warrant Common Stock | Dispose X | Yes | No | 11 | 161 | 1.77 k | 0 | |
24 Sep 24 | Levinson Mitchell E. | Warrant Common Stock | Dispose X | Yes | No | 11 | 161 | 1.77 k | 0 |
Press releases
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
21 Oct 24
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
12 Aug 24
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
12 Aug 24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
1 Aug 24
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
29 Jul 24